FDA limits stomach, esophageal cancer labels for Merck's Keytruda, Bristol Myers' Opdivo
The FDA late last month sent letters to Merck and Bristol Myers Squibb telling them that their blockbuster cancer drugs Keytruda and Opdivo should be limited to metastatic gastric, gastroesophageal junction and esophageal cancer in ...
The FDA late last month sent letters to Merck and Bristol Myers Squibb telling them that their blockbuster cancer drugs Keytruda and Opdivo should be limited to metastatic gastric, gastroesophageal junction and esophageal cancer in ...
